FRA:VX1 • US92532F1003
This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
VX1 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. VX1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VX1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, VX1 could be worth investigating further for growth and quality investing!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| ROIC | 15.14% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.04% | ||
| PM (TTM) | 32.94% | ||
| GM | 86.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 12.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.9 | ||
| Quick Ratio | 2.46 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.09 | ||
| Fwd PE | 24.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.19 | ||
| EV/EBITDA | 22.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (3/12/2026, 7:00:00 PM)
415.8
-10.8 (-2.53%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.09 | ||
| Fwd PE | 24.77 | ||
| P/S | 10.16 | ||
| P/FCF | 38.19 | ||
| P/OCF | 33.59 | ||
| P/B | 6.53 | ||
| P/tB | 7.11 | ||
| EV/EBITDA | 22.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| ROCE | 21.51% | ||
| ROIC | 15.14% | ||
| ROICexc | 24.16% | ||
| ROICexgc | 27.17% | ||
| OM | 39.04% | ||
| PM (TTM) | 32.94% | ||
| GM | 86.24% | ||
| FCFM | 26.61% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 208.58% | ||
| Cap/Sales | 3.65% | ||
| Interest Coverage | 377.85 | ||
| Cash Conversion | 74.18% | ||
| Profit Quality | 80.79% | ||
| Current Ratio | 2.9 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z | 12.64 |
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
ChartMill assigns a valuation rating of 4 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 9 / 10.
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.3% in the next year.